Bio Essence posts Q2 profit, revenue rebound but zero cash and going-concern warning

Quick take - Bio Essence Corporation (PINK: BIOE) - what's happening inside the company and the income-statement snapshot.

Key facts & figures

- Six months ended June 30, 2025 revenue: $281,312 (vs. $41,695 in 1H2024).
- Three months ended June 30, 2025 revenue: $259,123.
- Gross profit - 1H2025: $189,232; Q2 2025: $168,644 (gross margin ~67% for 1H; ~65% for Q2).
- Net loss from continuing operations - 1H2025: $(145,888). Q2 2025: net income from continuing ops $59,864.
- Total assets: $112,692; Total liabilities: $3,227,670; Stockholders' equity (deficit): $(3,114,978).
- Cash at period end: $0; cash at start of period: $1,371. Net increase (decrease) in cash for 1H2025: $(1,371).
- Working capital deficit (continuing ops) at June 30, 2025: ~$2.96M; current ratio ≈ 0.04:1.
- Operating lease liabilities (current): $1,387,840; non-current: $99,668. 2024 ROU impairment recorded: $1,050,940.
- Loans from shareholders on balance sheet: $1,036,777 (unsecured, non‑interest bearing, no written terms).
- Customer concentration (1H2025): two customers = 67.8% and 24.3% of sales. Vendor concentration for manufacturing service: two vendors = 77.7% and 22.3%.
- Shares outstanding: 38,009,000. NOL carryforwards ~ $2.50M (federal) with full valuation allowance - no deferred tax benefit recognized.
- Management's cash need estimate: ~$1.2M to operate for the next 12 months; going-concern disclosure included.

Positive signals

- Revenue rebound and business mix: large year-over-year lift in revenue driven by OEM/manufacture service (1H2025 $280k vs $0 in 1H2024).
- Strong gross margins on OEM services (~65-67%), indicating profitable unit economics before operating expenses.
- Q2 2025 produced positive operating result and net income from continuing operations: Q2 net income $59,864 - shows quarter-level profitability is achievable.
- Operating cash flow improved materially: net cash provided by operating activities from continuing operations of $141,728 for 1H2025 (vs. used $19,563 in 1H2024).

Negative / risk items (income statement & overall finances)

- Consolidated loss in 1H2025: continuing operations lost $(145,888). Company remains deeply cumulative-loss negative (accumulated deficit $10.595M).
- Zero cash at period end and a material working-capital deficit create immediate liquidity risk - operations depend on shareholder loans and external financing.
- Large legacy lease liability tied to an early-terminated facility: ROU impairment of $1.05M (2024), current lease liability ~$1.39M - cash/negotiation outcome uncertain; $50k deposit forfeiture previously recorded.
- Heavy reliance on related-party funding: >$1.03M of shareholder loans with no formal repayment terms or interest (concentration & governance risk).
- Customer and vendor concentration: two customers represent ~92% of sales (1H2025) and two vendors supply nearly all outsourced manufacturing - risks to revenue and margins if any relationship changes.
- Management warns of going-concern risk and estimates ~$1.2M needed to fund operations for 12 months - no assurance of successful fundraising.
- Internal control weaknesses: management concluded disclosure controls and internal control over financial reporting are not effective as of June 30, 2025.

Other items investors should watch

- Cash-raising activity (equity or third‑party financing) or conversion of shareholder loans into more permanent capital.
- Outcome of lease negotiations and any cash settlement related to the large operating lease liability.
- Customer retention and diversification - revenue concentrated in two customers.
- Margin sustainability as OEM revenue grows and outsourcing costs remain concentrated with a few vendors.
- Quarterly cadence: Q2 2025 shows profitability on a three‑month basis - confirmable trend or one-off.
- Any changes in related-party loan terms or new financing that reduce going-concern pressure.

Bottom line: Bio Essence Corporation (PINK: BIOE) moved revenue mix toward outsourced OEM services and achieved a profitable quarter (Q2 2025), but the company is cash‑constrained, highly leveraged by lease liabilities and shareholder loans, dependent on a tiny customer base and vendor pool, and faces a formal going‑concern warning. Investors should watch near‑term financing moves, lease resolution, and customer stability.